Table 1

Patient characteristics at baseline per dose level
Characteristics Dose level
1 2 3 Total
Number of patients 4 (100%) 13 (100%) 7 (100%) 24 (100%)
Age, years
N 4 13 6 23
Median (range) 55.5 (38–75) 65.0 (33–70) 56.0 (44–63) 62.0 (33–75)
Gender, n (%)
  Female 1 (25%) 2 (15%) 3 (13%)
  Male 3 (75%) 11 (85%) 7 (100%) 21 (88%)
KPS
  N 3 12 7 22
  Median (range) 100 (100–100) 90 (90–100) 100 (90–100) 95 (90–100)
Siewert classification
  AEG II 2 (50%) 9 (69%) 7 (100%) 18 (75%)
  AEG III 2 (50%) 4 (31%) 6 (25%)
T staging
3 3 (75%) 10 (77%) 6 (86%) 19 (79%)
4 1 (25%) 2 (15%) 1 (14%) 4 (17%)
X 1 (8%) 1 (4%)
N staging
0 2 (15%) 2 (8%)
1 2 (50%) 5 (38%) 4 (57%) 11 (46%)
2 2 (50%) 4 (31%) 2 (29%) 8 (33%)
X 2 (15%) 1 (14%) 3 (13%)
M staging
0 3 (75%) 12 (92%) 7 (100%) 22 (92%)
X 1 (25%) 1 (8%) 2 (8%)
UICC staging
II A 2 (15%) 2 (8%)
III 4 (100%) 8 (62%) 6 (86%) 18 (75%)
NK 3 (23%) 1 (14%) 4 (17%)

KPS, Karnofsky Performance Status.

UICC staging according to the 6th edition: NK in case of unknown T or N staging (Tx, Nx).

Moehler et al.

Moehler et al. BMC Cancer 2013 13:75   doi:10.1186/1471-2407-13-75

Open Data